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INTRODUCTION
Nitric oxide (NO) is not just a vasodila-
tor, but has several critical roles in the
maintenance of vascular homeostasis (1).
NO and Angiotensin II (AII) antagonize
each other in many vascular functions,
such as cell growth, apoptosis, and in-
flammation. AII has a central role in
the generation of oxidative stress in the
vessel wall (2).
An increased activity in the renin-
angiotensin system (RAS) has been shown
to be related closely to endothelial cell
(EC) dysfunction. Studies demonstrated
that a reduction in AII production by
ACE inhibitors restores EC function and
decreases cardiovascular events in high-
risk patients (3,4). Angiotensin I-
converting enzyme (ACE, peptidyl dipep-
tidase A, EC 3.4.15.1, kininase II) is a zinc
metalopeptidase that catalyzes the forma-
tion of AII and participates in vascular
tonus regulation and water and sodium
homeostasis (5,6). ACE is a major link be-
tween RAS and the kinin system, because
it not only converts AI to AII but also in-
activates bradykinin (5,7). ACE is found
as a membrane-bound enzyme anchored
by the hydrophobic carboxyl-terminal
segment and as a circulating molecule in
body fluids and is organized in two ho-
mologous domains, (N and 
C-domain) (8). ACE exists in at least two
different forms: somatic and testicular
ACE (9,10). ACE also was found in cere-
brospinal fluid (11) heart, blood vessels,
kidney, and in a freely soluble form in
plasma and urine (12,13). Casarini et al.
described two ACE isoforms in human
urine of normotensive subjects with 190
and 65 kDa and of hypertensive patients
with 90 and 65 kDa (both N-domain
ACE). Three isoforms with 190, 90, and 65
kDa were found in urine from offspring
with family history of hypertension. Stud-
ies using animal models suggested that
the 90 kDa ACE could be a possible ge-
netic marker of hypertension (13–16).
Endothelial dysfunction (ED) is con-
sidered an early event in the develop-
ment of atherosclerosis, and several stud-
ies have demonstrated the presence of
ED in hypertensive patients (17). Basal
M O L  M E D  1 4 ( 7 - 8 ) 4 2 9 - 4 3 5 ,  J U L Y - A U G U S T  2 0 0 8  |  F E R N A N D E S  E T  A L .  |  4 2 9
Association of Urinary N-Domain Angiotensin I-Converting
Enzyme with Plasma Inflammatory Markers and Endothelial
Function
Fernanda B Fernandes,1 Frida L Plavnik,1,3 Andressa MS Teixeira,1 Dejaldo MJ Christofalo,2 Sergio A Ajzen,2
Elisa MS Higa,1,4 Fernanda A Ronchi,1 Ricardo CC Sesso,1 and Dulce E Casarini1,3
Address correspondence and reprint requests to Dulce Elena Casarini, Universidade Fed-
eral de São Paulo, Escola Paulista de Medicina, Departamento de Medicina, Disciplina
de Nefrologia, Rua Botucatu, 740, CEP 04023-900, São Paulo, SP, Brasil. Phone: 55 11 5574
6300; Fax: 55 11 5573 96 52; E-mail: dulce@nefro.epm.br.
Submitted October 31, 2007; Accepted for publication April 30, 2008; Epub (www.molmed.
org) ahead of print May 5, 2008.
1Department of Medicine, Nephrology Division, 2Department of Image Diagnostic, 3Oswaldo Ramos Foundation, and 4Emergency
Division, Federal University of São Paulo, São Paulo, Brazil
The aim of this study was to investigate the association between urinary 90 kDa N-domain Angiotensin I-converting enzyme
(ACE) form with C-reactive protein (CRP) and homocysteine plasma levels (Hcy), urinary nitric oxide (NOu), and endothelial func-
tion (EF) in normotensive subjects. Forty healthy subjects were evaluated through brachial Doppler US to test the response to re-
active hyperemia and a panel of blood tests to determine CRP and Hcy levels, NOu, and urinary ACE. They were divided into
groups according to the presence (ACE90+) or absence (ACE90–) of the 90 kDa ACE, the presence (FH+) or absence (FH–) of
family history of hypertension, and the presence or absence of these two variables FH+/ACE90+ and FH–/ACE90–. We found an
impaired endothelial dilatation in subjects who presented the 90 kDa N-domain ACE as follows: 11.4% ± 5.3% in ACE90+ com-
pared with 17.6% ± 7.1% in ACE90– group and 12.4% ± 5.6% in FH+/ACE90+ compared with 17.7% ± 6.2% in FH–/ACE90– group,
P < 0.05. Hcy and CRP levels were statistically significantly lower in FH+/ACE90+ than in FH–/ACE90– group, as follows: 10.0 ± 2.3 μM
compared with 12.7 ± 1.5 μM, and 1.3 ± 1.8 mg/L compared with 3.6 ± 2.0 mg/L, respectively. A correlation between flow-
mediated dilatation (FMD) and CRP, Hcy, and NOu levels was not found. Our study suggests a reduction in the basal NO pro-
duction confirmed by NOu analysis in subjects with the 90 kDa N-domain ACE isoform alone or associated with a family history of
hypertension. Our data suggest that the presence of the 90 kDa N-domain ACE itself may have a negative impact on flow-
mediated dilatation stimulated by reactive hyperemia.
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NO synthesis may be the first detectable
evidence of endothelial dysfunction.
ED is present in healthy normotensive
subjects who are at high risk for the de-
velopment of essential hypertension (18).
Although there is a general agreement
that endothelium-dependent vasodilata-
tion is impaired in patients with essential
hypertension, the relationship between
this defect and plasma concentrations of
nitric oxide is unclear (17).
Most cardiovascular risk factors
have been recognized to promote a pro-
inflammatory state (19). Among them,
arterial hypertension has been related to
many circulating inflammatory markers
such as C-reactive protein (CRP) and
homocysteine (Hcy), (20–22) indepen-
dently of other risk factors, promoting
the idea of hypertension as a potentially
pro-inflammatory condition (22). Stud-
ies have clearly established that CRP
predicts a future risk of cardiovascular
disease in apparently healthy people
(23). The mechanism linking Hcy with
cardiovascular disease may be the in-
duction of vascular damage, although
the exact mechanism is not understood
fully. On the other hand, some prospec-
tive studies have shown only a weak or
no relationship between homocysteine
and cardiovascular disease (24).
Our purpose is to test the hypothesis
that the presence of the 90 kDa N-
domain ACE form in human urine
could be associated with ED and inflam-
matory markers such as CRP and Hcy




This is a cross-sectional study of male
normotensive subjects, ranging in age
from 18–40 years, with (FH+) and with-
out (FH–) a family history of essential
hypertension (EH).
Subjects
A total of 40 healthy male volunteers
age ranging from 18–40 years were in-
cluded in this study. Hypertension was
defined as blood pressure levels above
140/90 mmHg. Women were not in-
cluded in this study due to the protective
effect of estrogen that might interfere with
our results. None of the subjects had any
significant past medical history, nor were
they taking any medication or vitamins
before or during the study, and all were
nonsmokers. The subjects were initially
divided into two groups according to the
presence or absence of essential hyperten-
sion in at least one parent. The next step
was based on the presence (+) or absence
(–) of the 90 kDa N-domain ACE isoform,
irrespective of FH, and finally we com-
bined the presence of FH and the pres-
ence of 90 kDa N-domain ACE isoform
which was compared with the group
where both conditions were absent.
This study was conducted in accor-
dance with the Guidelines for Good
Clinical Practice and the Declaration of
Helsinki after approval by the Ethics
Committee on Human Experimentation
from the Federal University of São
Paulo. Informed consent was obtained
from all volunteers.
Blood Pressure Measurement
Subjects underwent a physical exami-
nation, which included weight and
height measurements to determine
body mass index (BMI), measurement
of waist (W) and hip (H), and combined
calculation of their ratio (WHR). Physi-
cian investigators measured blood
pressure using a mercury column
sphygmomanometer and a cuff of ap-
propriate size. The standardized proto-
col involved measurement of systolic
and diastolic blood pressures in the left
arm after participants had been seated
quietly for 5 min, at intervals of 1 min
for 3 min. The heart rate (HR) also was
measured. A mean of these BP values
was used for further analyses. Biochem-
ical profile was determined from blood
samples collected after a 12 h overnight
fast. Those who presented with any lab-
oratorial abnormality were excluded
from the study. Afterward, they were
scheduled for a brachial artery reactive
test to evaluate FMD.
Purification of the Angiotensin
Converting Enzymes from Human
Urine Samples
The urine was concentrated in Centri-
con concentrator (Millipore, Billerica MA,
USA) and dialyzed in the same equip-
ment against 50 mmol/L Tris-HCl, pH 8.0,
containing 150 mmol/L NaCl using a
30 kDa molecular weight exclusion mem-
brane. The concentrated urine (1.0 mL)
was submitted individually to a gel fil-
tration on an AcA-44 column (16 × 840
mm) previously calibrated with standard
proteins (Amersham Pharmacia Biotech,
San Francisco CA, USA). Fractions (1.0 mL)
were collected at a flow rate of 20 mL/h.
Protein concentration was monitored
by absorbance at 280 nm and ACE activ-
ity was measured using Z-Phe-His-Leu
(Z-PheHL) as substrate (25,26). The pro-
tein levels of urine and purified enzymes
were determined by the Bradford method
(Bio-Rad Protein Assay, Hercules CA, USA)
using bovine albumin as standard, except
when absorbance at 280 nm was used for
chromatographic elution profile (27).
Western Blotting
Western blotting was performed using
100 μg of urinary protein. SDS-PAGE was
performed as described by Laemmli (28).
After the electrophoretical transference of
the proteins from the polyacrylamide gel
to a nitrocellulose membrane (Hybond P,
Amersham Biosciences, Piscataway NJ,
USA) it was incubated overnight at room
temperature with antibody Y4 diluted
1:1000 (29). The secondary antibody was
an anti-rabbit Ig (Whole Ab) (GE Health-
care, Vppsal, Sweden). Subsequent steps
were carried out using the biotin/strepta-
vidin system (Amersham Pharmacia
Biotech, Vppsal, Sweden) as recom-
mended by the manufacturer.
Endothelial Function Assessment
The endothelial function test was
performed by high-resolution B-mode
ultrasound images using a non-invasive
methodology described by Celenmajer et
al. (30). The equipment used in this
study was an Ultramark HDI 3000 (ATL
ultrasound incorporation), with a linear
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transducer of L7-4 MHz. Examinations
were performed in an air-conditioned
room at a temperature of ~22° C. To
avoid circadian variations, all examina-
tions took place in the morning. This test
assessed FMD after reactive hyperemia.
Diameter and blood flow velocities were
determined in triplicate. The maximum
blood flow (mL/min) was determined
in the first 15 s after cuff release. Ninety
seconds after ischemia, three measure-
ments of the diameter of the brachial ar-
tery were taken during the diastole pe-
riod. FMD response was expressed as
the change in end-diastolic diameter of
the brachial artery during reactive hyper-
emia compared with the baseline mea-
surement and used as a measure of en-
dothelium-dependent vasodilatation.
Homocysteine Levels Determination
Concentrations of plasma homocys-
teine levels were measured by high per-
formance liquid chromatography (HPLC,
Shimadzu, Kyoto, Japan) with a column
Prodigy ODS2, 150 × 3.2 mm × 5 μm
(Phenomenex, Torrance, CA, USA) as
described by Pfeiffer et al. (31) and
adapted by Nunes et al. (32).
Urinary Nitric Oxide Levels (NOu)
The NO was determined in urine by
the chemiluminescence method as de-
scribed by Ribeiro et al. (33). We used the
Model 280 Nitric Oxide Analyzer (NOA)
(Sievers Instruments Inc., Boulder, CO,
USA). The sensitivity for measurement
of NO and its reaction products is ap-
proximately 1 picomole.
C-Reactive Protein quantification
Concentrations of plasma C-reactive
protein levels were measured by a
chemiluminescence method with an au-
tomated IMMULITE system.
Statistical Analysis
Data were expressed as mean ± stan-
dard deviation (SD). Urinary nitric oxide
concentrations were transformed loga-
rithmically to normalize the distribution.
The unpaired Student t-test or analysis
of variance (ANOVA) were used, as
appropriate, to compare means of contin-
uous variables. Correlation between vari-
ables was assessed by the Pearson′s cor-
relation coefficient. Linear regression
analysis was performed considering %
FMD as the dependent variable, and as
independent variables: age, BMI, lipid
profile, CRP, Hcy, and NOu. A P value
< 0.05 was used to indicate statistical
significance. Statistical analyses were
performed using the SPSS software
(SPSS 10.1 for Windows, USA).
RESULTS
Clinical, biochemical, and demo-
graphic characteristics of subjects were
divided according to presence (FH+, 
n = 26) or absence (FH–, n = 14) of fam-
ily history of high blood pressure.
There was no statistically significant
difference between these two groups
(data not shown).
The urine samples of subjects were
submitted to DAE-cellulose chromatog-
raphy. Three peaks with ACE activity
were detected in subjects with family
history of hypertension with molecular
weight of 190, 90, and 65 kDa and two
peaks with 190 and 65 kDa in subjects
without family history of hypertension
(Figures 1A,B). The urine was studied by
Western blot analysis using the antibody
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Figure 1. Gel filtration chromatography of human urine: 1.0 mL of concentrated urine
from normotensive subjects (A): with family history of hypertension (FH+) and (B): without
family history of hypertension (FH–) were submitted separately to gel filtration on an
AcA-44 column equilibrated and eluted as described in the Methods section. Fractions
of 1.0 mL were collected at a flow rate of 20 mL/h; (—) Optical Density (OD) 280 nm;
(—) ACE activity on Z-PheHL as substrate.
(Y4) raised against human kidney ACE
(Figure 2A,B).
The same subjects were divided into
other groups according to presence (90
kDa+, n = 33) or absence (90 kDa–, n = 7)
of the N-domain ACE, and according to
presence or absence of family history of
hypertension plus presence or absence of
the enzyme, FH+/ACE90+ (n = 23) and
FH–/ACE90– (n = 4), respectively (Table 1).
A family history of high blood pressure
was reported in 65% of subjects and the
90 kDa N-domain ACE isoform was de-
tected in 82%. The ACE activity in the
urine of subjects with 90 kDa ACE iso-
form tended to be higher than in subjects
without this isoform (0.37 ± 0.37 com-
pared with 0.27 ± 0.26 mU/mg, respec-
tively). The same profile was found in the
FH+/ACE90+ group (0.41 ± 0.37 mU/mg)
compared with FH–/ACE90– group
(0.2 ± 0.2 mU/mg).
The results of baseline blood flow
were analyzed and there were no statisti-
cally significant differences between the
groups studied (data not shown). We
found no statistically significant differ-
ences between baseline vascular diame-
ter of the subjects. These results were:
0.39 ± 0.04 in ACE90+ compared with
0.38 ± 0.05 cm in ACE90– group and
0.39 ± 0.04 in FH+/ACE90+ compared
with 0.38 ± 0.04 cm in FH–/ACE90–.
We found an impaired endothelial
dilatation in subjects who presented
the 90 kDa N-domain ACE as follows:
11.4% ± 5.3% in ACE90 + compared with
17.6% ± 7.1% in ACE90– group, P < 0.05,
and 12.4% ± 5.6% in FH+/ACE90+ com-
pared with 17.7% ± 6.2% in FH–/ACE90–
group, P < 0.05 (Figure 3). These results
of FMD correspond to lower urinary ni-
tric oxide concentrations in the groups
that have impaired endothelial function.
The values of log (NOu) were 6.8 ± 0.8 in
ACE90+ and 7.2 ± 0.5 μM in ACE90–
group. For the groups FH+/ACE90+ and
FH–/ACE90–, the corresponding values
were, respectively, 6.9 ± 0.9 compared
with 7.2 ± 0.5, which were not found
statistically significantly different.
The homocysteine levels were lower
in the ACE 90 kDa+ than in the ACE 90
kDa– group (9.9 ± 2.6 μM compared
with 11.4 ± 2.8 μM), and the comparison
reached statistical significance between
the groups FH+/ACE90+ and FH–/
ACE90– (10.0 ± 2.3 μM compared with
12.7 ± 1.5 μM, P < 0.05). The same profile
was found for CRP levels, the values
were lower in the ACE 90 kDa+ than in
the ACE 90 kDa– group (1.3 ± 1.7 mg/L
compared with 2.3 ± 2.2 mg/L). The lev-
els were significantly lower in the FH+/
ACE90+ than in the FH–/ACE90– group
(1.3 ± 1.8 mg/L compared with 3.6 ±
2.0 mg/L, P < 0.05). We did not detect
any statistically significant association
between FMD and inflammatory mark-
ers, or between FMD and NOu.
DISCUSSION
In the present study, we investigated
the association of urinary 90 kDa ACE
N-domain isoform and CRP, Hyc plasma
levels, urinary nitric oxide, and endothelial
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Figure 2. Western blotting analysis of urine:
Expression analysis of urinary proteins was
done with the use of Y4 polyclonal anti-
ACE antibody. (A): Normotensive subjects
with family history of hypertension (FH+):
Lane 1 standard (Rainbow, Amersham
Biosciences, Sweden) 2, 3, and 4, urine
from three different subjects FH+. (B): Lane
5 standard (Rainbow, Amersham Bio-
sciences, Sweden), lane 6, subject without
family history of hypertension (FH–). Arrows
indicate bands recognized by the anti-
body and the standards.
Table 1. Clinical characteristics of the studied subjects from the different groups.
ACE ACE P FH+/ FH–/ P
90 kDa+ 90 kDa- value ACE90+ ACE90- value
Age, years 27.9 ± 7.01 27.4 ± 6.0 0.403 29.4 ± 6.8 27.7 ± 7.9 0.646
Systolic BP, mmHg 110.9 ± 7.1 110.7 ± 5.4 0.410 110.8 ± 7.2 112.5 ± 3.9 0.255
Diastolic BP, mmHg 74.7 ± 6.0 73.3 ± 8.3 0.550 74.6 ± 5.7 74.5 ± 6.0 0.760
BMIa, Kg/m2 25.2 ± 3.4 25.7 ± 3.6 0.706 25.2 ± 3.6 27.5 ± 3.9 0.900
HR, bpm 66 ± 4 69 ± 10 0.414 67 ± 8 68 ± 12 0.497
Creatinine, umol/L 97 ± 7 97 ± 10 0.184 97 ± 7 97 ± 8 0.577
Glucose, mmol/L 4.3 ± 0.4 4.2 ± 0.5 0.410 4.3 ± 0.4 4.0 ± 0.4 0.765
Total Cholesterolb 4.3 ± 0.92 4.7 ± 0.78 0.787 4.4 ± 0.95 5.0 ± 0.8 0.814
Triglyceridesb 1.2 ± 0.7 1.06 ± 0.4 0.206 1.17 ± 0.6 1.0 ± 0.2 0.052
HDL-Cholesterolb 1.3 ± 0.3 1.4 ± 0.4 0.870 1.3 ± 0.4 1.5 ± 0.4 0.798
LDL-Cholesterolb 2.5 ± 0.8 2.7 ± 1.2 0.330 2.6 ± 0.9 2.8 ± 1.7 0.131
NOuc 6.8 ± 0.8 7.2 ± 0.5 0.271 6.9 ± 0.9 7.2 ± 0.5 0.253
ACE activity (mU/mg) 0.37 ± 0.37 0.27 ± 0.26 0.089 0.41 ± 0.37 0.2 ± 0.2 0.077
CRP (mg/L)d 1.3 ± 1.7 2.3 ± 2.2 0.202 1.3 ± 1.8 3.6 ± 2.0 P < 0.05
Homocysteine μM 9.9 ± 2.6 11.4 ± 2.8 0.952 10.0 ± 2.3 12.7 ± 1.5 P < 0.05
aBMI indicates body mass index.
bTotal Cholesterol, Triglycerides, HDL-C and LDL-C (mmol/L).
cUrinary nitric oxide indicates NOu-μM (log).
dC-Reactive Protein indicates CRP.
dysfunction in healthy subjects with or
without a family history of hypertension.
The differences between all groups
studied for clinical data, biochemistry,
and demographics were not statistically
significant.
A family history of high blood pres-
sure was found in 65% of the subjects
and the 90 kDa ACE isoform was de-
tected in 82% of the subjects. The pres-
ence of 90 kDa isoform was not found in
all subjects with a history of high blood
pressure, this may be because the family
giving information is subjective or that
the genetic alterations responsible for
inherited essential hypertension remain
largely unknown (34). We found three
ACE isoforms with 190, 90, and 65 kDa
in the urine of offspring with a family
history of hypertension, but in subjects
without family history of high blood
pressure, only two isoforms with 190
and 65 kDa. The presence of 90 kDa ACE
isoform was analyzed by gel filtration
chromatography and confirmed by West-
ern blotting. This result is in agreement
with our previous study where 90 kDa
N-domain ACE was reported to be segre-
gated and may be a very important fac-
tor in the conversion of a normotensive
subject to hypertensive, and also was
related to hypertension in a crossing and
retro-crossing of Spontaneously Hyper-
tensive and Brown Norway rats (13–16).
The presence of 90 kDa and 65 kDa ACE
has been the target of several studies.
The literature suggests that mechanisms
of solubilization are involved in forming
these isoforms by shedding with a secre-
tase or (35–37), by an alternative splicing
of the ACE mRNA (38,39).
Patients with the ACE90 kDa+ had a sig-
nificantly reduced endothelium-dependent
vasodilatation response of the brachial
artery when compared with patients
without this isoform (ACE 90 kDa–):
11.4% ± 5.3% compared with 17.6% ±
7.1%, P = 0.014, respectively. Patients with
90 kDa ACE associated with a family his-
tory of hypertension also had a negative
impact on FMD and the percentage was:
12.4% ± 5.6% in FH+ /ACE90+ compared
with 17.7% ± 6.2% in FH–/ACE90– group
(P < 0.05). The data of Taddei et al. (40)
indicated that Ach-mediated forearm va-
sodilatation is reduced in normotensive
subjects with a family history of essential
hypertension, a finding that suggests that
endothelium dysfunction can precede the
appearance of hypertension, and that this
abnormality might play a role in patho-
genesis of hypertension.
An impaired trend was observed in
relation to NOu, where subjects with 90
kDa ACE had a lower urinary nitric
oxide concentration than those who did
not have this isoform (6.8 ± 0.8 compared
with 7.2 ± 0.5 log μM, respectively). In
relation to the groups FH+/ACE90+ and
FH–/ACE90–, these concentrations were
6.9 ± 0.9 compared with 7.2 ± 0.5 respec-
tively. Although no statistically signifi-
cant difference was found in relation to
NOu, these findings are compatible with
the ultrasound results. There is a general
agreement that endothelial-dependent
vasodilatation is impaired in patients
with essential hypertension (17,41), but
the relationship between this defect and
plasma concentrations of nitric oxide is
not clear. Our results agree with Lyamina
et al. (42) who showed that 24 h urinary
excretion of Nox was significantly lower
in patients with stage I and II hyperten-
sion than in control subjects, and signifi-
cantly lower in patients with stage II hy-
pertension than in patients with stage I
hypertension.
ACE catalytic activity was determined
using Z-Phe-His-Leu as substrate de-
scribed as a specific substrate to N-do-
main ACE portion (37). Subjects with
90 kDa ACE isoform had higher enzy-
matic urinary activity when compared
with the group without the 90 kDa ACE.
The same tendency was observed in the
group that had this isoform associated
with a family history of high blood pres-
sure, suggesting that subjects who have
ACE 90 kDa may be more susceptible to
hypertension (15).
Examination of lipidic profile showed
that the group with 90 kDa isoform had
higher triglyceride levels than the group
without the urinary isoform, as shown in
results. When we analyzed the presence
of 90 kDa ACE associated with a history
of hypertension (FH+/ACE90+ and
FH–/ACE90– groups), we found the
same profile without a statistically signif-
icant difference. HDL-C levels were
lower in subjects with 90 kDa ACE iso-
form than in those without it being simi-
lar to the results obtained for subjects
with FH+/ACE90+ compared with
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Figure 3. Percentage of flow-mediated dilatation (FMD) in subjects with ACE 90 kDa (ACE
90 kDa+), without this isoform (ACE 90 kDa–); subjects with family history of hypertension
and the 90 kDa isoform (FH+/ ACE 90 kDa+), and subjects without these two variables
(FH–/ACE 90 kDa–). *P < 0.05.
FH–/ACE–. This difference was not sta-
tistically significant, but may suggest
that patients with 90 kDa ACE isoform
could have a major risk of developing
atherosclerosis.
There was no significant correlation
between FMD, CRP, and homocysteine
levels in any of the subjects studied. The
study of Chrysohoou et al. (22) revealed
differences in the markers, such as CRP
and homocysteine, between prehyperten-
sive and normotensive subjects without
any clinical evidence of cardiovascular
disease. They found homocysteine levels
higher in prehypertensive (13.9 μM) and
hypertensive (14.1 μM) compared with
normotensive subjects (13.1 μM). They
hypothesized about a direct relationship
between borderline blood pressure levels
and inflammation process. We did not
detect a relationship between BP and Hcy.
The highest value found was 12.7 μM,
which is not considered hyperhomocys-
teinemia by Refsum et al. (43). The analy-
sis of our results shows that subjects
with 90 kDa ACE had Hcy levels lower
than those who did not have this iso-
form. This finding was not statistically
significant. Instead, the analysis of the
presence of an urinary isoform associ-
ated with a history of high blood pres-
sure presents a statistical difference be-
tween the groups FH+/ACE90+ and
FH–/ACE90–. We cannot suggest a cor-
relation between Hcy and 90 kDa ACE.
The CRP levels detected in all groups
studied do not have any correlation with
the presence of 90 kDa ACE isoform. Ac-
cording to Clapp et al. (44), the enormous
range of CRP levels in vivo argues
strongly against this CRP having a major
role in the modulation of vascular tone.
In conclusion, our data indicated that
reduced endothelial vasorelaxant proper-
ties shown in 90 kDa N-domain ACE
subjects can be detected prior to the
onset of high blood pressure. This find-
ing might suggest a primary endothe-
lium defect allied to the presence of 
90 kDa N-domain ACE isoform and
higher levels in its urinary activity that
can play a role in the pathogenesis of
essential hypertension.
In summary, our findings suggested
that subjects with the 90 kDa ACE with a
family history of hypertension presented
endothelial dysfunction under sub-clinical
conditions. These data support the prem-
ise that these parameters antedate the
onset of hypertension. The predictive
value of these possible biomarkers (for
example, 90 kDa N-domain ACE and
endothelial dysfunction) could be used
for assessing future hypertension risk.
Studies with a large population would
be necessary to use these biomarkers for
predicting hypertension, which is consid-
ered a critical public health problem.
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